Qualcomm continues to have a rough start to the first half of the year after being sued by Apple and the United States Federal Trade Commission in separate lawsuits over anti-competitive practices. On Friday, Samsung and Intel both filed briefs backing the FTC in its case against Qualcomm, claiming they have been “harmed” by the misconduct.
Although Samsung develops its own chips that compete with Qualcomm’s, it uses its competitor’s chips in its smartphones — such as the Snapdragon 835 processor in the Galaxy S8. “Despite having requested a license from Qualcomm, Samsung cannot sell licensed Exynos chipsets to non-Samsung entities because Qualcomm has refused to license Samsung to make and sell licensed chipsets,” Samsung said in its brief, calling Qualcomm’s actions “exclusionary.”
Intel, on the other hand, claims in its filing that Qualcomm’s practices have “inflicted and continues to inflict precisely the harms that the antitrust laws seek to protect against,” according to The Wall Street Journal.
“Qualcomm has maintained an interlocking web of abusive patent and commercial practices that subverts competition on the merits. These practices have illegally coerced mobile phone manufacturers into purchasing the chipsets they need from Qualcomm and Qualcomm alone,” Intel wrote.
While Qualcomm has not commented on Samsung and Intel’s briefings, it did warn investors in its most recent earnings report that growing legal challenges may affect its financial outlook. Qualcomm’s motion to dismiss the FTC suit is slated for June, and will be heard in a federal court in the Northern District of California.
Full Content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas